Meet Eurofins at BEBPA EUR Bioassay Conference 2024!
CONTACT USEurofins BioPharma Product Testing (BPT) Germany is excited to participate in the 17th Annual Hybrid European Bioassay Conference, taking place from September 25-27, 2024, in Prague, Czech Republic. This leading event is a key gathering for professionals in the analytical biopharmaceutical field, featuring three days of presentations, workshops, and round-table discussions.
Event Details:
Date: September 25-27, 2024
Location: Hilton Prague Hotel, Prague, Czech Republic
Join us on September 27 at 16:15 for our presentation:
Title: From Manual to Automated: Case Studies for Increasing Bioassay Precision and Throughout by Adding Modular Components in Bioassay Workflow
Speaker: Dr. Frances Reichert, Technical Specialist Biologics, Eurofins BioPharma Product Testing Germany GmbH
Abstract: For Quality Control (QC) of biopharmaceuticals, release of batches and stability assessments require in vitro cell-based (bio-)potency assays (CBA). These assays inherit intrinsic variability, primarily due to the use of living cells and factors like pipetting steps, assay complexity, and analyst experience. Despite advances in automation, implementing full automation remains challenging in a GMP environment. We focused on semi-automation of potency assays in a modular manner, automating specific parts of the assay. This presentation will showcase several case studies demonstrating how modular workflow automation can enhance the reliability, precision, and throughput of potency assays.
Join us on September 26 at 13:00 for the Luncheon Talk:
Title: Moving the Scale for Biotherapeutics from Bench to Bedside: Developing Qualified Cell-based Assays
Speakers: Dr. Bettina Katterle of Eurofins BioPharma Product Testing (Munich) & Gaurav Agrawal, Ph.D. of Eurofins DiscoverX
Abstract: Here we present the development and qualification of cell-based assays using FACS, (semi-) automation methods for testing of biotherapeutics, ATMPs, and peptides. Case studies for Tirzepatide, a global blockbuster weight-loss agent that engages GLP-1 and GIP receptors will be shown. Recently approved peptide therapeutics such as Semaglutide and Tirzepatide targeting GPCRs have demonstrated remarkable efficacy in managing obesity, type 2 diabetes, and an expanding range of associated conditions. To effectively develop these innovative drugs, as well as their biosimilar and biobetter derivatives, pharmacologically relevant assays are essential. These assays are crucial for understanding the precise mechanism of action, and establishing desired pharmacological profile, in addition to ensuring reliable measurements.
Meet us at BEBPA EUR Bioassay Conference 2024
Schedule a meeting and make sure to meet our team:
Thank you for requesting the meeting at BEBPA 2024!- Expertise and Innovation
Meet our team to discover advanced solutions and services in pharmaceutical quality control, ensuring excellence in safety, efficacy, and compliance. - Exclusive Presentations
Join our sessions to learn about the latest advancements in bioassay testing, new methodologies, and regulatory updates. Enhance your knowledge and streamline your processes. - Networking Opportunities
Connect with industry leaders, professionals, and peers. Discuss your challenges and opportunities with our experts to explore potential collaborations. - Personalized Consultations
Book a one-on-one consultation with our specialists for customized advice and solutions tailored to your specific needs. We’re here to help with optimizing testing processes and meeting regulatory requirements.
We look forward to engaging with you at the 2024 Hybrid European Bioassay Conference!
About Eurofins BioPharma Product Testing:
Eurofins BioPharma Product Testing is the largest network of harmonized bio/pharmaceutical GMP product testing laboratories worldwide providing comprehensive laboratory services for the world's largest pharmaceutical, biopharmaceutical and medical device companies.
Our service offerings are fully comprehensive and include testing of drug substance, final product, intermediates, and starting materials for both small and large molecule drug products.
We give clients the flexibility to choose from three service models to meet specific project needs, including the award-winning PSS Insourcing Solutions® and we also provide secure 24-hour data access via our online data portal, LabAccess.comSM.
Our laboratories offer a broad range of methodologies under GMP authorization, ISO 17025 accreditation and ISO 9000 certification and all analysis are performed according to European and British Pharmacopeia (EP and BP), United States Pharmacopeia (USP) and Japanese Pharmacopeia (JP), as well as specific customer methods.
With a global capacity of more than 200,000 square meters and facilities located in Australia, Belgium, Canada, Czech Republic, Denmark, France, Germany, India, Ireland, Italy, Japan, Netherlands, New Zealand, Slovakia, Spain, Sweden, Switzerland, UK and the US, our network of GMP laboratories operates under the same strict quality procedures, LIMS and centralized billing system across more than 45 locations worldwide.
